Company news

Aquestive Therapeutics, Inc. news in 2023

Aquestive Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film

December 4, 2023

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

November 9, 2023

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 5, 2023

Aquestive Therapeutics Completes $45 Million Debt Refinancing

November 1, 2023

Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8: 00 a.m. ET

October 30, 2023

Aquestive Therapeutics Provides Business Update

October 8, 2023

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

September 19, 2023

Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date

September 10, 2023

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 6, 2023

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

August 1, 2023

Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film

July 26, 2023

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8: 00 a.m. ET

July 24, 2023

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference

July 24, 2023

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit

July 5, 2023

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

June 28, 2023

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

May 30, 2023

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023

Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)

April 19, 2023

Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8: 00 a.m. ET

April 17, 2023

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets

March 28, 2023

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

March 6, 2023

Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

February 28, 2023

Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8: 00 a.m. ET

February 21, 2023

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

February 20, 2023

Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

January 5, 2023

Calls in 2023

Decks in 2023